A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors

Clinical trial NCT05592626 · RECRUITING

Trial details

NCT number: NCT05592626
Sponsor: Marengo Therapeutics, Inc.
Status: RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Advanced Solid Tumors Genital Neoplasm, Female Urogenital Neoplasms Lung Neoplasm Neoplasms by Site Papillomavirus Infection Epstein-Barr Virus Infections Carcinoma Neoplasms Vulvar Neoplasms Vulvar Diseases Abdominal Neoplasm

Start date: 2023-01-04
Primary completion: 2027-09-01
Enrollment: 366

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.